China Slashes GLP-1 prices by as much as 80% due to rising rates of obesity
A fierce price war is reshaping China’s weight-loss market as companies slash costs by up to 80 percent to capture their share of a rapidly expanding sector. The competition intensified following the 2024 approval of obesity treatments from global leaders Novo Nordisk and Eli Lilly, with both...
rudevulture.com
